Ahsan, A., Mantis, C., Luo, A., Zheng, P., Liu, W., Zhang, C., Rodriguez, C., Voorhees, P., D'Souza, A., Chung, A., Tuchman, S., Safah, H., Mckay, J., Weisel, K., Teipel, R., Korde, N., Vij, R., Kumar, S., Baljevic, M., Mian, H., Pothacamury, R. K., Svensson, A., Talati, C., Ross, J. (2025). Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses. Blood. https://doi.org/10.1182/blood-2025-2204